Patients with venous bypass grafts are at risk of having atherosclerotic degeneration of the graft.lV3 Both short-and long-term results after balloon dilatation of this type of lesion, and notably angioplasty of completely occluded grafts, appear to be less favorable than results in native coronary arteries.4-6 In approximately 3 % of patients the procedure may be complicated by peripheral embolization of the bypass atheroma, resulting in peripheral occlusion and myocardial infarction. 4, 6 The restenosis rate in dilated venous bypass grafts is higher than that in native vessels; particularly the proximal anastomosis is prone to restenosis (46 % 1, the risk is intermediate in the shaft of the vein graft (35%) and lowest at the distal anastomosis (24% ).8 It has been reported that only 46% of patients were symptom free 5 years after angioplasty of a saphenous vein graft compared with 79% after balloon dilatation of native vessels.g
Recently it has been suggested that stent implantation at the dilatation site may improve both shortand long-term results. 1o,11 Evaluation of the use of these devices may be even more appealing in view of the increasing number of patients that have recurrent angina after venous bypass grafting.g The aim of this analysis was to assess the need for anticoagulation therapy to prevent thrombotic complications after successful stent implantation in venous bypass grafts. Obviously the risk of complications inherent in anticoagulation therapy should compare favorably with the possible gain in safety, improved success rate, and better immediate hemodynamic results when these new interventions are applied in a highrisk patient population.
METHODS

Patients.
The patient population consisted of 24 consecutive patients who had previously undergone venous aortocoronary bypass surgery and had recurrent angina pectoris (Canadian Heart Association class III to IV). The 1389 complaints were typical and were documented by ST segment abnormalities either at rest or during exercise. Symptoms had to have been present for more than 7 days and unresponsive to maximal drug treatment without signs of recent myocardial infarction. All patients were discussed with the cardiothoracic surgeon and were considered not to be good candidates for reoperation on the basis of their coronary anatomy and the expected gain from surgery. In view of the stringent anticoagulation that had to be applied after stent implantation, all patients were screened for the presence of any bleeding disorders. For this reason patients with recent gastrointestinal bleeding, cerebrovascular accident, or other bleeding disorders did not undergo stent implantation. This report focuses on elective procedures; therefore two patients with evolving myocardial infarction and two with stent implantation in an occluded bypass at the time of the study will not be discussed. The mean age of the 20 men and four women was 63.6 years (+ 9.4). Six patients had hypertension and five had hypercholesterolemia. Diabetes mellitus was diagnosed in seven patients; three patients were insulin dependent, three were taking oral medication, and one was following a sugar-free diet.
Three patients were current smokers. The average ejection fraction was 56% (range 0.26 to 0.70).
The implantation procedure is described in detail elsewhere.13-l5 In seven patients the stent was implanted without angioplasty, and in 21 the implantation was preceded by balloon angioplasty. In five patients balloon angioplasty was performed before and after stent implantation; in the remaining five the lesion was stented and angioplasty was subsequently performed in the stented artery ("Swiss kiss"). Catheters were introduced either viasheaths in the femoral artery by percutaneous puncture according to the Seldinger technique (n = 22) or by direct dissection of the brachial artery (n = 2). At the end of the procedure the brachial vessels were surgically closed. Femoral sheaths were left in place during the ensuing 24 hours; the next day the sheaths were removed 2 hours after heparin was discontinued; 1 hour later heparin was resumed.
The average interval since the last bypass surgery was 72.8 months (range 1 to 166). The average number of bypass grafts was 1.4 (range 1 to 3). Thirty-five lesions were stented with 46 stents; the stenosis was located in the ostium in four patients, in the shaft in 21, at the proximal anastomosis in six, and distally in five. In seven patients two stents were positioned in a telescoping manner, and in two patients three overlapping stents were implanted. In the remaining patients, one prosthesis was positioned at the stenosis. Medication given before stent implantation and at 3 months' follow-up is summarized in Table I . Nine patients were receiving anticoagulation therapy (acenocoumarin or phenprocoumon) before stent implantation and 19 at 3 months' follow-up.
Drug protocol before, during, and after implantation.
The protocol for drug treatment consisted of administration of oral dipyridamole (4 x 75 mg), sulfinpyrazone (4 X 200 mg), and salicylic acid (2 X 500 mg on the day before implantation and 1 X 100 mg thereafter), as well as nifedipine (3 x 20 mg), which was started before stent implantation and continued for approximately 3 months (Table II) . Before balloon dilatation heparin, 10,000 IU, and dextran, 500 mg/4 hr, were given intravenously. Immediately after stent implantation 100,000 to 250,000 IU of urokinase was administered intracoronarily, followed by an additional 100,000 IU during the next 60 minutes. Intravenous heparin was continued at a minimal dosage of 24,000 IU/24 hr; the dosage was adjusted to double or triple the activated partial thromboplastin time (APTT). If the APTT exceeded 180 seconds, the infusion was interrupted for 1 hour and resumed at a dosage that was decreased by 5000 IU/24 hr. Heparin was continued but the dosage was reduced by 5000 IU/24 hr when the APTT was between 120 and 180 seconds. If the APTT was less than 70 seconds or twice control values, the dosage was increased by 5000 IU/24 hr and the APTT was controlled 8 hours later. Oral acenocoumarol was started on the day of implantation; heparin infusion was continued until prothrombin time measured by thrombotest (TT) was lowered to 5 ?; to 10 % for two subsequent days and was slowly discontinued thereafter. intravascular stent. The self-expanding stent consisted Baseline hemostatic parameters.
Twelve hours before of 16 metal alloy filaments (outer diameter 0.08 mm) that formed a geometrically stable tubular meshwork; the maximal outer diameter of the device that was attained after implantation was determined on the one hand from the radial forces generated by the device and on the other hand from the vascular elasticity of the vascular wa11.i2 In the unconstrained state the maximal diameter ranged from 3.5 to 6 mm (mean 4.2 mm) with a length that varied from 15 to 30 mm (mean 22 mm). Before implantation the stent was stretched and mounted on the tip of a 5F central-hole catheter; subsequently the device was covered by a coaxial balloon that was removed during the procedure. To ascertain continuous outward compression of the vascular wall after implantation, the unconstrained diameter of the stent was chosen to exceed the measured reference diameter of the stenosed area by approximately 0.5 mm. According to the TT, coagulation activity was expressed as a percentage of control activity. In the presence of anemia or polycythemia, the values were corrected according to the specifications of the assay. TT measurements may seemingly be lowered during concomitant heparin administration; in our patients this effect was not compensated for by neutralization of serum samples with protamine sulfate."" Instead TT was determined daily until heparin was gradually discontinued when TT values were within the therapeutic range.
RESULTS
Stent implantation.
The angiographic results after stent implantation were evaluated by means of quantitative angiography, with an automated edge-detection technique. I49 23-2.5 Before balloon dilatation the mean luminal diameter of the stenosed bypass was 1.5 mm + 0.9 (range 0.7 to 2.9). The mean estimated reference bypass diameter at the stenosis (interpolated technique) was 3.4 mm + 1.1 (range 1.6 to 7.0), and the average diameter of the angioplasty balloon was 3.2 mm & 0.6 (range 2 to 4.2). The unconstrained diameter of the stent that was implanted after balloon dilatation was 4.1 mm +-0.7 (range 3.5 to 6.0). All procedures were successful and without complications.
The procedure allowed easy delivery of the device without misplacement and reduced the diameter of the stenosis to <50%. There were no acute bypass occlusions. Immediately after angioplasty and stent implantation, the mean diameter of the lesion was 2.0 ( + 0.6) and 2.8 ( -t 0.9) mm, respectively.
Baseline hemostatic parameters.
Baseline coagulation parameters are summarized in Table III. Before  stent implantation, TT, PT, and APTT were all outside the normal range, which was accounted for treatment with oral or intravenous anticoagulants in almost half of the patients (see Drug protocol before, during, and after implantation.)
Fibrinogen levels were strikingly elevated as well. The changes in the coagulation parameters during and after stent implantation are shown in Fig. 1 . Initially the mean APTT (closed circles, SEM as bars) increased to 120 seconds and thereafter stabilized around 80 seconds. As soon as the thrombotest values had decreased between 5 % and 10 % on days 2 to 3, heparin was gradually discontinued, resulting in normalization of the APTT. Note that two patients had early occlusion of the stented graft. In patient A the occlusion (day 2) coincided with suboptimal anticoagulation treatment; in patient B anticoagulants had to be discontinued on day 7 after implantation as a result of acute gastrointestinal bleeding (see below).
Comptications (Table IV) . Four patients had hematomas with a diameter exceeding 5 cm, resulting in anemia that had to be corrected by blood transfusions. One patient had a transient attack, but fortunately the clinical condition normalized without sequelae. As mentioned previously patient A, who initially had two stents implanted, had a recurrence of angina pectoris after 3 months; results of repeat angiography showed severe stenosis proximal to the implanted stents. This was corrected by balloon angioplasty followed by implantation of two additional stents. However, 3 days later the patient again had angina. Results of recatheterization showed that the peripheral native vessels supplied by the stented bypass graft showed thrombi that were not present on the angiogram before the second implantation. Subsequently it was decided to perform a reoperation, which was uneventful.
Patient B (Fig. 2) had upper gastrointestinal bleeding in spite of the absence of gastrointestinal complaints before the intervention. As a result of continuous vomiting with blood loss and melena, heparin and acenocoumarol were discontinued, Subsequently the patient had angina with ECG signs of myocardial ischemia (i.e., negative T waves) without elevation of creatine kinase levels. During recatheterization it appeared that this was related to impending occlusion of the bypass by a fresh thrombus located outside the stented segment. Subsequently, repeat coronary bypass surgery was performed without evidence of perioperative myocardial infarction.
A third patient had an uneventful implantation of one stent. However, on day 7 he had an acute myocardial infarction (maximal creatine kinase level, 706 U/L) without signs of congestive heart failure. Results of recatheterization showed total occlusion of the bypass within the stent, notwithstanding adequate anticoagulation therapy. In one patient continued blood loss from the sutured brachial artery necessitated surgical reexploration; a false aneurysm of the brachial artery was sutured and the vessel reconstructed by means of a venous flap. The subsequent clinical course was uneventful, and the patient was given anticoagulants and discharged. One patient had hematuria without anemia. Our results show that stent implantation after balloon angioplasty of stenosed venous bypass grafts is technically feasible and successful at an early stage, provided that the patients are carefully selected. To be a candidate for stent implantation, each patient was were any recent bleeding, cerebral hemorrhage, severe liver or kidney dysfunction, thrombocyte dysfunction, thrombocytopenia, or hypertension (> 180/l 10 mm Hg), and diabetic or hypertensive retinopathy.
For this reason complete hematologic and coagulation status was obtained from all patients before the intervention, and stool samples were checked for the presence of microscopic blood loss. Notwithstanding these precautions, one patient had upper gastrointestinal bleeding, necessitating interruption of the anticoagulation therapy. Another important determinant of the ultimate success is the regional anatomy of the coronary arteries that are supplied by the diseased venous bypass graft. In our previous experience with stenting of coronary arteries, poor distal runoff, small diameter of the stenosed vessel, and previous myocardial infarction in the region supplied by the stenosed artery, as well as haziness of the dilated lesion, were contraindications for stent implantation. Our favorable results within the first day may be explained, at least in part, by the diameter of the venous grafts, which exceeded the luminal diameter of native coronary vessels by a factor of 1.5 to 3.
In general the extensive anticoagulation therapy was continued until 3 months after stent implantation. The rationale for this approach is based on observations in animal experiments; it has been reported that stents that were implanted in pig femoral arteries were completely covered by endothelium within 1 to 3 weeks. 26 Since histologic data in humans are still lacking, we decided not to risk acute thrombotic occlusion and therefore continued anticoagulation therapy until 3 months after implantation. Stringent anticoagulation was accomplished by scrupulous and frequent monitoring of the coagulation status of each patient for approximately 3 months. It is conceivable that in some patients the burden of frequent visits to the outpatient clinic and extensive medication may compromise the quality of life to such an extent that it would have been preferable to perform bypass surgery despite the possibility of increased risk of myocardial infarction or even death as a result of the latter procedure. The possible advantageous long-term effects of stent implantation on the rate of restenosis should be well established to gain acceptance as an alternative to bypass surgery. Thus long-term follow-up including quantitative angiography of treated patients is necessary and is currently under investigation. 
The adequacy of anticoagulation therapy May 1991
American Heart Journal was controlled by assessing the TT (in percentages) and APTT levels (in seconds). The concept of the thrombotest was initially introduced by Owren.lg It is well known that coumarin derivatives, such as acenocoumarol or phenprocoumon, prevent incorporation of vitamin K in coagulation factors II, VII, IX, and X. Consequently inactive proteins induced by the absence of vitamin K (or antagonists) are formed.16 The resulting lengthening of coagulation time may be measured by means of the thrombotest; the test assesses the serum coagulation time in the presence of excess kefaline, thrombokinase, factors V and VIII, and calcium chloride. The assay is sensitive to the presence of coagulation factors II, VII, (IX), and X and is more or less equivalent to the PT as measured by the Quick test. Normal thrombotest values of 40 seconds or less have been reported in healthy control subjects; in our patients the preferable TT level ranged between 180 and 210 seconds, which is equivalent to a thrombotest value of 5% to 10% (international normalized ratio 2.5 to 5). According to the manufacturer, thrombotest values may be seemingly increased in the presence of heparin. 22 Although this does not seem relevant in daily clinical practice, this effect may be compensated for by neutralization of the serum before the test. We preferred to gradually discontinue heparin administration and frequently monitored TT at the same time.
plications may have resulted from local thrombogenie mechanisms that were triggered by the interaction of the self-expanding stent with the more compliant vessel wall. To prevent these acute thrombotic complications, we applied stringent anticoagulation therapy after successful implantation of the stent. The rationale for the drug treatment was to provide maximal antithrombotic effects by interference with the normal function of platelets and endothelial lining and by inhibition of coagulation factors.
The effect of heparin administration was adjusted according to the APTT. The patient's pretreatment APTT (30 to 35 seconds) was increased by a factor of 2 or 3. The white cell count appeared elevated after the procedure in almost every patient; this may have been caused by acenocoumarol, which may induce redistribution of white cells, notably neutrophils, as has been reported recently.27 However, in our patients the observed leukocytosis may be equally well accounted for by hematoma formation and subsequent resorption.
As a result of stent implantation the intimal lining of the venous graft was damaged, which may have given rise to aggregation of platelets and formation of thrombin.28 Therefore platelet aggregation was antagonized by aspirin and sulfinpyrazone, both of which inhibit production of thromboxane Agzg, :j"; dipyridamole, on the other hand, was administered in an attempt to inhibit platelet deposition and aggregation to damaged vessels because of increased production of platelet c-AMP.~I, 32 Thrombin formation was prevented by administration of heparin and if present lysed by urokinase, thereby preventing acute occlusion.33, 34 Vasospasm, which may be triggered by release of vasoactive agents during angioplasty, was prevented by nifedipine and diltiazem.3" Dextran (Rheomacrodex) was infused, since this inert plasma volume expander is known to reduce platelet adhesiveness and platelet aggregation induced by injury to the vessel wa11.36, 37 In addition, it reduces factor VIII activity38 and increases clot lysability."g It remains to be seen whether this extensive anticoagulation regimen is an absolute requirement for prevention of the complications of acute thrombosis. A less extensive protocol may appear equally effective for prevention of early thrombotic complications after stent implantation in venous bypass grafts.40 In addition, the number of patients with complications induced by the stringent anticoagulation regimen may be reduced. We conclude that stent implantation after per-
The stents that were implanted in our patients cutaneous transluminal coronary angioplasty of were not coated. It has been reported that heparinstenosed venous bypass grafts may result in normalor polymer-coated stents may be advantageous, since ization of the regional hemodynamic profile. Unforendothelial cell proliferation is enhanced by various tunately the drastic improvement in rheologic conanticoagulation and antiplatelet drugs, as was shown ditions, as evidenced by the virtual disappearance of in cell cultures. Notably low-molecular-weight heppoisseuille resistance and normalization of laminar arin seems to exert a favorable effect on endothelial flow,14 was inadequate to prevent thrombotic comcell growth. 41 Future designs for stents should inplications in three patients. Our observations thereclude polished endings for the wires that form the fore suggest that the primary cause of thrombotic device; alternatively the device could be covered by occlusion must be ascribed to the thrombogenic naa layer of endothelial cells or polymer or corticoid ture of the stent itself or to its direct thrombogenic coating to prevent early thrombotic occlusion and interaction with the diseased and atherosclerotic endothelial proliferation for the longer term.4" More vessel wall. Likewise the observed thrombotic comrecently it has been suggested that the device be cov-Number 5 ered with heparin benzalkonium chloride complex (H-BAC), which is known to prevent thrombosis. Other designs such as biodegradable devices, may also prove useful and diminish the rate of restenosis.
To prevent some of the bleeding complications, anticoagulation therapy, notably acenocoumarin, may be considered 1 day before stent implantation. Likewise removal of the arterial sheaths immediately after the procedure rather than 12 hours later could reduce the number of severe hematomas.
Recently it was suggested that the effects of heparin administration be monitored by measurement of activated clotting time during and after percutaneous transluminal angioplasty.43 The same technique could be applied equally well in patients after stent implantation.
Since the method is reliable, cheap, and easy to perform, it may be considered more frequently to adjust heparin administration and attain an optimal coagulation status. Introduction and application of these and other laboratory techniques without any doubt will reduce the risk of thrombotic occlusions resulting from inadequate heparin administration. 
